ClinicalTrials.gg
RecruitingNCT02004509SILENTUpdated Sep 1, 2021

Subclinical AtrIal FibrilLation and StrokE PreveNtion Trial

A Phase 4 interventional study of Anticoagulant in Atrial Fibrillation, sponsored by InCor Heart Institute. Recruiting at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-01.

Sponsored by InCor Heart Institute · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Feb 2015; still recruiting 11 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2,054
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 56 studies in Atrial Fibrillation with a site in Brazil — 10 open to participants now, 12 under way, 4 of them phase 3. Atrial Fibrillation · Brazil.

Planned enrollment
23rd of 49
2,054 · median 1,504
Started
2015
with 1 other
Phase 4
9 of 56
3 open now
Primary completion
2025-10
later than 0 of 11 live
Registered
24th of 56
by date

Among the 56 studies in Atrial Fibrillation with a site in Brazil, this one is the 23rd largest by planned enrollment of the 49 interventional ones that give a count, is one of 2 that started in 2015, is one of 9 in phase 4, reaches primary completion later than 0 of the 11 other live ones, and was the 24th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

10 of the 56 studies in Atrial Fibrillation with a site in Brazil are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Atrial Fibrillation with a site in Brazil, or all of them as a file.
02

Study summary

Introduction: Patients with atrial fibrillation (AF) have a substantial risk of stroke and systemic embolism. Subclinical AF is often suspected to be the cause of stroke in these patients. The detection of asymptomatic AF episodes is a challenge and the real rate of occurrence of these episodes remains unknown. The rate of stroke is high among patients who have received a pacemaker and this device can detect subclinical episodes of rapid atrial rate, which correlate with electrocardiographically documented AF. The net benefit of anticoagulant treatment is well established in patients with clinical AF but data about anticoagulation in subclinical AF setting is unknown. The aim of this study is to assess the impact of anticoagulant therapy on subclinical AF, directed by cardiac implantable electronic device (CIED) intensive monitoring, on the incidence of stroke and systemic embolism and correlate the AF episodes detected by CIED with thromboembolic events. Methods: This is a prospective, randomized, unicentric, parallel clinical study in patients with atrioventricular pacemaker, defibrillator, or cardiac resynchronization therapy devices in sinus rhythm and CHADS2 score (an index of the risk of stroke in patients with atrial fibrillation, range from 0 to 6) ≥ 2 . Patients will be randomized to the intervention group - intensive monitoring arm (Group I) or control group - routine schedule arm (Group II) in a 1:1 ratio. Time to inclusion will be 24 months and all patients will be followed up for a period of 36 months. Group I, patients will be submitted to device data collection every 2 months, while in Group II, patients will be managed conventionally. Patients from Group I with episodes of subclinical AF will receive anticoagulant therapy, as well as patients with clinical AF of both arms. Device data from Group II patients will not be analyzed until they achieve the primary endpoint. Primary endpoint: stroke or systemic embolism. Secondary endpoints: subclinical AF rate, total mortality, cardiovascular mortality, myocardial infarction, cardiovascular hospitalization, and bleeding rates. Expected outcome: It is expected that anticoagulation therapy of subclinical AF directed by CIED intensive monitoring will reduce the incidence of stroke and systemic embolism comparing to patients with non-diagnosed subclinical AF.

Read the detailed description

Patients with atrial fibrillation (AF) have a substantial risk of stroke and systemic embolism. Subclinical AF is often suspected to be the cause of stroke in these patients. The detection of asymptomatic AF episodes is a challenge and the real rate of occurrence of these episodes remains unknown. The rate of stroke is high among patients who have received a pacemaker and this device can detect subclinical episodes of rapid atrial rate, which correlate with electrocardiographically documented AF. The net benefit of anticoagulant treatment is well established in patients with clinical AF but data about anticoagulation for subclinical AF settings is unknown. The aim of this study is to assess the impact of anticoagulant therapy on subclinical AF, directed by cardiac implantable electronic device (CIED) intensive monitoring, on the incidence of stroke and systemic embolism and correlate the AF episodes detected by CIED with thromboembolic events. Methods: This is a prospective, randomized, unicentric, parallel clinical study in patients with an atrioventricular pacemaker, defibrillator, or cardiac resynchronization therapy devices in sinus rhythm and CHADS2 score (an index of the risk of stroke in patients with atrial fibrillation, range from 0 to 6) ≥ 2 . Patients will be randomized to the intervention group - intensive monitoring arm (Group I) or control group - routine schedule arm (Group II) in a 1:1 ratio. Time to inclusion will be 24 months and all patients will be followed up for a period of 36 months. Group I, patients will be submitted to device data collection every 2 months, while in Group II, patients will be managed conventionally. Patients from Group I with episodes of subclinical AF will receive anticoagulant therapy, as well as patients with clinical AF of both arms. Device data from Group II patients will not be analyzed until they achieve the primary endpoint. Primary endpoint: stroke or systemic embolism. Secondary endpoints: subclinical AF rate, total mortality, cardiovascular mortality, myocardial infarction, cardiovascular hospitalization, and bleeding rates. Expected outcome: It is expected that anticoagulation therapy of subclinical AF directed by CIED intensive monitoring will reduce the incidence of stroke and systemic embolism comparing to patients with non-diagnosed subclinical AF.

03

Conditions studied

  • Atrial Fibrillation

Keywords

  • atrial fibrillation
  • stroke
  • pacemaker
  • anticoagulant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >= 18 years
  • CHADS2 score >=2
  • Sinus rhythm
  • Cardiac Implantable Electronic Device

Exclusion criteria

Exclusion Criteria:

  • Atrial fibrillation
  • Severe heart valve disease
  • Anticoagulation therapy
  • Pregnancy
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,054 participants (estimated)

Study arms

  • Active comparator
    anticoagulant

    Prescription of oral anticoagulation for patients with silent AF (detected by the pacemaker).

    Drug: Anticoagulant

  • No intervention
    Control

    Patients with silent FA detected only by the pacemaker will no receive oral anticoagulation.

Interventions

  • DrugAnticoagulant

    Anticoagulant treatment will be started in case of subclinical atrial fibrillation (\>5,5 hours per day) be diagnosed by cardiac implantable electronic device at intervention group, or clinical atrial fibrillation in both groups.

    Also known as: Oral Anticoagulant

06

What researchers measure

Primary outcomes

  1. Stroke

    Occurrence of stroke

    Time frame: 36 months

  2. Systemic embolism

    Occurrence of systemic embolism

    Time frame: 36 months

Secondary outcomes

  1. Subclinical AF rate

    Rate subclinical AF documentation by pacemaker

    Time frame: 36 months

  2. Total mortality

    All cause mortality

    Time frame: 36 months

  3. Cardiovascular mortality

    Adjudicated cardiovascular mortality

    Time frame: 36 months

  4. Myocardial infarction

    Occurrence of myocardial infarction

    Time frame: 36 months

  5. Cardiovascular hospitalization

    Adjudicated cardiovascular hospitalization

    Time frame: 36 months

  6. Bleeding rates

    Occurrence of bleeding

    Time frame: 36 months

07

Study locations

1 of 1 sites recruiting
  • Martino Martinelli Filho
    São Paulo, Sao Paulo 05403-900, Brazil
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2015 (actual). Primary completion is estimated for Oct 2025, 128 months after the start.

Of 130 non-industry phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 81. This study's planned 128 months is above that.

Counting every sponsor, half of 142 studies reached it within 48 months; a quarter within 27 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2013
First posted
Dec 9, 2013
StartActual
Feb 6, 2015
Primary completionEst.
Oct 31, 2025
CompletionEst.
Oct 31, 2025
Last update
Sep 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02004509
Lead sponsor
InCor Heart Institute
Responsible party
Martino Martinelli Filho (Prof., MD, InCor Heart Institute) — Principal investigator
First posted
Dec 9, 2013
Start date
Feb 6, 2015
Primary completion
Oct 31, 2025 (estimated)
Completion
Oct 31, 2025 (estimated)
Last update
Sep 1, 2021

Study contacts

Martino Martinelli Filho, PhD, MD
Contact
martino@incor.usp.br
+551126615515
Sergio F Siqueira, Eng
Contact
siqueira@incor.usp.br
+5511973083052
Sergio F Siqueira, Eng
study director · Biomedical Eng

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion